DE69534472D1 - Transkriptionsmodulatoren tetracyklin-regulierte - Google Patents

Transkriptionsmodulatoren tetracyklin-regulierte

Info

Publication number
DE69534472D1
DE69534472D1 DE69534472T DE69534472T DE69534472D1 DE 69534472 D1 DE69534472 D1 DE 69534472D1 DE 69534472 T DE69534472 T DE 69534472T DE 69534472 T DE69534472 T DE 69534472T DE 69534472 D1 DE69534472 D1 DE 69534472D1
Authority
DE
Germany
Prior art keywords
tet operator
tetracycline
analogue
absence
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534472T
Other languages
English (en)
Other versions
DE69534472T2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TET Systems Holding GmbH and Co KG
Original Assignee
TET Systems Holding GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/275,876 external-priority patent/US5654168A/en
Priority claimed from US08/383,754 external-priority patent/US5789156A/en
Application filed by TET Systems Holding GmbH and Co KG filed Critical TET Systems Holding GmbH and Co KG
Application granted granted Critical
Publication of DE69534472D1 publication Critical patent/DE69534472D1/de
Publication of DE69534472T2 publication Critical patent/DE69534472T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
DE69534472T 1994-07-01 1995-06-29 Transkriptionsmodulatoren tetracyklin-regulierte Expired - Lifetime DE69534472T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27063794A 1994-07-01 1994-07-01
US08/275,876 US5654168A (en) 1994-07-01 1994-07-15 Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US08/383,754 US5789156A (en) 1993-06-14 1995-02-03 Tetracycline-regulated transcriptional inhibitors
US08/486,814 US5866755A (en) 1993-06-14 1995-06-07 Animals transgenic for a tetracycline-regulated transcriptional inhibitor
PCT/US1995/008179 WO1996001313A1 (en) 1994-07-01 1995-06-29 Tetracycline-regulated transcriptional modulators

Publications (2)

Publication Number Publication Date
DE69534472D1 true DE69534472D1 (de) 2006-02-02
DE69534472T2 DE69534472T2 (de) 2006-06-14

Family

ID=27501005

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0804565T Pending DE804565T1 (de) 1994-07-01 1995-06-29 Transkriptionsmodulatoren tetracyklin-regulierte
DE69534472T Expired - Lifetime DE69534472T2 (de) 1994-07-01 1995-06-29 Transkriptionsmodulatoren tetracyklin-regulierte

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE0804565T Pending DE804565T1 (de) 1994-07-01 1995-06-29 Transkriptionsmodulatoren tetracyklin-regulierte

Country Status (13)

Country Link
US (2) US5866755A (de)
EP (2) EP0804565B1 (de)
JP (3) JP4054058B2 (de)
CN (2) CN1523112A (de)
AT (1) ATE305034T1 (de)
AU (1) AU3092395A (de)
CA (1) CA2193122C (de)
DE (2) DE804565T1 (de)
DK (1) DK0804565T3 (de)
ES (1) ES2139552T3 (de)
FI (1) FI965287A (de)
NO (1) NO315375B1 (de)
WO (1) WO1996001313A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
AU684524B2 (en) 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5851796A (en) * 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
GB9526509D0 (en) * 1995-12-23 1996-02-28 Univ Dundee Gene control
DE19635568C1 (de) * 1996-09-02 1998-03-26 Gsf Forschungszentrum Umwelt Vektorsysteme zur konditionalen Genexpression
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
DE19707493C1 (de) * 1997-02-25 1998-02-26 Univ Ludwigs Albert Nucleinsäurekonstrukte zur lang andauernden Expression von Transgenen
AU745049B2 (en) 1997-03-11 2002-03-07 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
PL336523A1 (en) 1997-04-28 2000-07-03 Rhone Poulenc Rorer Sa Intraneoplastic delivery of an angiogenesis antagonist by means of adenoviruses in order to treat neoplasms
US6087166A (en) * 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
US20030040038A1 (en) * 1997-08-22 2003-02-27 Steven F. Dowdy Inducible regulatory system and use thereof
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
US6576469B1 (en) 1997-09-10 2003-06-10 President And Fellows Of Harvard College Inducible methods for repressing gene function
CA2306448A1 (en) 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
EP1721986A1 (de) * 1997-10-29 2006-11-15 Genetics Institute, LLC Schnellerzeugung von stabilen Säugertier-Zelllinien mit Gewinnung eines hohen Gehalts von rekombinanten Proteinen
US6136536A (en) * 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US5968773A (en) * 1997-11-14 1999-10-19 Heddle; John A. System and method for regulation of gene expression
ES2308327T3 (es) * 1997-11-18 2008-12-01 Pioneer Hi-Bred International, Inc. Composiciones y metodos para modificacion genetica de plantas.
DE19751587A1 (de) 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
DE19756975A1 (de) 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
DE69926729T2 (de) 1998-01-08 2006-06-08 Aventis Pharmaceuticals Inc. Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
JP2002508972A (ja) * 1998-01-16 2002-03-26 ファルマシア・アンド・アップジョン・カンパニー テトラサイクリン−制御可能なエレメントを用いる可能な抗微生物標的としての微生物遺伝子を確認するための自律制御系
US6878516B1 (en) 1998-01-16 2005-04-12 Pharmacia & Upjohn Company Autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
EP1151119A1 (de) * 1999-02-09 2001-11-07 Rhobio Verfahren zur hemmung der expression von zielgenen in pflanzen
US6291226B1 (en) 1999-02-25 2001-09-18 National Research Council Of Canada Adenovirus mutants with deleted protease gene
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
WO2000068399A2 (en) * 1999-05-11 2000-11-16 Regents Of The University Of Minnesota Vector-mediated delivery of integrating transposon sequences
WO2001000815A1 (en) * 1999-05-28 2001-01-04 Sangamo Biosciences, Inc. Molecular switches
WO2000075347A2 (en) * 1999-06-07 2000-12-14 Wolfgang Hillen Tet repressor-based transcriptional regulatory proteins
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｄ−１、ｂ７−４の受容体、およびその使用
AU784883B2 (en) 1999-12-30 2006-07-20 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
WO2001088192A2 (en) 2000-05-12 2001-11-22 The Johns Hopkins University A method for generating hypermutable organisms
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2811681A1 (fr) * 2000-07-17 2002-01-18 Commissariat Energie Atomique Procede de criblage de la translocation nucleo-cytoplasmique de proteines sous l'effet d'un stimulus, d'elements y etant impliques et kits de mise en oeuvre
JP2004505647A (ja) * 2000-08-18 2004-02-26 ジヤンセル・エス・アー 条件的阻害によるトランスジーンの発現をインビボで調節する方法
FR2813085A1 (fr) * 2000-08-18 2002-02-22 Aventis Pharma Sa Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7129343B2 (en) * 2001-02-13 2006-10-31 University Of Florida Bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
EP1385946B1 (de) 2001-05-01 2009-12-23 National Research Council Of Canada Induzierbares expressionssystem in eukaryotischen zellen
US20030221203A1 (en) * 2001-10-03 2003-11-27 Agha-Mohammadi Siamak High efficiency regulatable gene expression system
AU2002362084A1 (en) * 2001-12-07 2003-07-09 University Of Massachusetts Zinc finger-based drug-dependent gene regulation system
CA2481244A1 (en) * 2002-04-15 2003-10-23 Universitatsklinikum Hamburg-Eppendorf Recombining viral vectors for the tetracycline-regulated expression of genes
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
DK1531666T3 (da) * 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DK1532260T3 (da) 2002-08-28 2009-03-09 Tet Systems Holding Gmbh & Co Kromosomale lod til stringent regulering af genaktiviteter via transkriptionsaktiveringssystemer
FR2845692A1 (fr) * 2002-10-15 2004-04-16 France Hybrides Procede pour produire un mammifere rendu resistant a une infection par un alpha herpes virus par transgenese germinale ainsi que mammifere obtenu par la mise en oeuvre de ce procede
AU2003296438A1 (en) * 2002-12-24 2004-07-29 North Carolina State University Increasing gamete production with a gene switch
US8293503B2 (en) 2003-10-03 2012-10-23 Promega Corporation Vectors for directional cloning
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2005046450A2 (en) 2003-11-12 2005-05-26 Children's Hospital Medical Center Method for diagnosis and treatment of pulmonary disorders
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
WO2007032555A1 (ja) * 2005-09-15 2007-03-22 Japan Science And Technology Agency テトラサイクリン系抗生物質によるタンパク質分解制御法
EP1926459B1 (de) 2005-09-19 2015-01-07 Histogenics Corporation Zellunterstützende matrix mit eng definierter, gleichmässig senkrecht und nicht zufällig organisierter porosität und porendichte und verfahren zur herstellung davon
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
DK1954811T3 (da) * 2005-11-17 2011-07-04 Tet Systems Gmbh & Co Kg Inducerbare ekspressionssystemer
AU2006323315B2 (en) 2005-12-09 2014-02-20 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
CA2652347A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
BRPI0714981A2 (pt) 2006-07-28 2013-08-13 Sanofi Aventis composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
DE602007012460D1 (de) * 2006-10-23 2011-03-24 Res Org Information & Systems Igkeit zur tetracyclin-induzierten genexpression oder eines zellstamms mit konditionalem gen-knockout sowie verwendung der zellstämme
EP2135945B1 (de) 2007-03-14 2014-04-23 Japan Science and Technology Agency Verfahren zur doppelten regulation von transkription/abbau für ein protein mittels antibiotikum
ES2628973T3 (es) 2007-05-31 2017-08-04 University Of Washington Mutagénesis inducible de genes diana
CA2739192A1 (en) 2008-10-01 2010-04-08 Tet Systems Gmbh & Co.Kg Tetracycline inducible transcription control sequence
RU2532854C2 (ru) * 2008-10-28 2014-11-10 Пайонир Хай-Бред Интернэшнл, Инк. Сульфонилмочевина-реактивные репрессорные белки
WO2010054221A2 (en) 2008-11-06 2010-05-14 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
EP2366796A1 (de) * 2010-03-09 2011-09-21 Friedrich-Alexander-Universität Erlangen-Nürnberg Mittel und Verfahren zur Identifizierung von Verbindungen, die die Zellkernlokalisierung von Proteinen verändern
WO2011153440A2 (en) 2010-06-04 2011-12-08 Regents Of The University Of Minnesota Transposon mutagenesis system and methods of use
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
EP2643459B1 (de) 2010-11-24 2017-09-27 Takara Bio USA, Inc. Transkriptionsmodulatoren mit einem system für induzierbare expression und einer domäne für verteilte proteintransduktion
PL2646466T3 (pl) 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012135549A2 (en) 2011-03-29 2012-10-04 Dynavax Technologies Corporation Tlr8 transgenic animals
US9822379B2 (en) 2011-05-19 2017-11-21 Fundación Pública Andaluza Progreso Y Salud Highly inducible dual-promoter lentiviral TET-ON system
WO2013033407A2 (en) 2011-08-30 2013-03-07 The Regents Of The University Of California Identification of small molecules that enhance therapeutic exon skipping
JP5871304B2 (ja) * 2011-09-06 2016-03-01 大学共同利用機関法人自然科学研究機構 テトラサイクリン遺伝子発現誘導システムにおける発現量を増幅させる遺伝子座とノックインによる増幅の効果
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP2878674A1 (de) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stabile Episomen auf Basis von nichtintegrativen lentiviralen Vektoren
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
WO2017109654A1 (en) * 2015-12-23 2017-06-29 Basf Se Pamamycin controlled systems for gene expression
CN107344962B (zh) * 2016-05-04 2021-03-02 中国科学院微生物研究所 阻遏蛋白、调控元件组和基因表达调控系统及其构建方法
CN108823208B (zh) * 2018-06-29 2021-11-02 中国科学院过程工程研究所 一种四环素诱导启动子及其制备方法和应用
CA3117992A1 (en) 2018-11-08 2020-05-14 Sutro Biopharma, Inc. E coli strains having an oxidative cytoplasm
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
IL301292A (en) 2020-09-14 2023-05-01 Sutro Biopharma Inc A method for the large-scale production of antibodies using a cell-free protein synthesis system
EP4314302A1 (de) 2021-03-24 2024-02-07 Dna Twopointo Inc. Tetracyclininduzierbare expressionssysteme
WO2022217142A1 (en) * 2021-04-09 2022-10-13 Washington University Compositions and methods for treatment of crx-linked retinopathies
EP4349979A1 (de) 2021-05-27 2024-04-10 Institute Of Zoology, Chinese Academy Of Sciences Manipulierte cas12i-nuklease, effektorprotein und verwendung davon
CN114085874B (zh) * 2022-01-10 2022-04-29 广东乾晖生物科技有限公司 一种制备肝功能可逆的永生化肝细胞的方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
FR2628453B1 (fr) * 1988-03-08 1990-11-16 Cofpa Procede de pose d'une toile autour d'un cylindre et dispositif de pre-tension pour la mise en oeuvre du procede
US5221778A (en) * 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
GB8901676D0 (en) * 1989-01-26 1989-03-15 Ici Plc Regulation of gene expression
AU649228B2 (en) * 1989-07-28 1994-05-19 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Efficient directional genetic cloning system
WO1991013979A1 (en) * 1990-03-05 1991-09-19 President And Fellows Of Harvard College Transgenic mouse overexpressing il-4 and method of use
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
JPH05507853A (ja) * 1990-06-12 1993-11-11 ベイラー・カレッジ・オブ・メディシン 動物細胞および植物細胞における相同的組換え法
AU8059891A (en) * 1990-06-13 1992-01-07 Trustees Of Princeton University, The A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells
JPH06503967A (ja) * 1991-01-04 1994-05-12 ベイラー・カレッジ・オブ・メディシン 腫瘍感受性非ヒト動物
DE4100594A1 (de) * 1991-01-08 1992-07-09 Inst Genbiologische Forschung Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen
JP3293622B2 (ja) * 1991-03-15 2002-06-17 エイチエスシー リサーチ アンド ディヴェロップメント リミテッド パートナーシップ 形質転換された魚類の製造用の遺伝子構築体
WO1992020808A1 (en) * 1991-05-15 1992-11-26 Cell Genesys, Inc. Genomic modifications with homologous dna targeting
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5917122A (en) * 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
EP1978095A1 (de) * 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Regulierte Transkription gezielter Gene und anderer biologischer Ereignisse
AU684524B2 (en) * 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters

Also Published As

Publication number Publication date
JPH11506901A (ja) 1999-06-22
ATE305034T1 (de) 2005-10-15
DK0804565T3 (da) 2006-02-06
WO1996001313A1 (en) 1996-01-18
US5866755A (en) 1999-02-02
JP2007295938A (ja) 2007-11-15
EP1092771A3 (de) 2001-08-01
US20040003417A1 (en) 2004-01-01
EP0804565A1 (de) 1997-11-05
CN1523112A (zh) 2004-08-25
JP2008011862A (ja) 2008-01-24
FI965287A0 (fi) 1996-12-31
EP0804565B1 (de) 2005-09-21
DE69534472T2 (de) 2006-06-14
NO315375B1 (no) 2003-08-25
DE804565T1 (de) 2000-05-04
NO965623D0 (no) 1996-12-30
ES2139552T3 (es) 2006-04-16
JP4820344B2 (ja) 2011-11-24
CN1167504A (zh) 1997-12-10
JP4682176B2 (ja) 2011-05-11
EP1092771A2 (de) 2001-04-18
ES2139552T1 (es) 2000-02-16
JP4054058B2 (ja) 2008-02-27
NO965623L (no) 1997-02-28
CA2193122A1 (en) 1996-01-18
EP1092771B1 (de) 2012-12-12
CA2193122C (en) 2005-08-23
AU3092395A (en) 1996-01-25
FI965287A (fi) 1997-02-28

Similar Documents

Publication Publication Date Title
ATE305034T1 (de) Transkriptionsmodulatoren tetracyklin-regulierte
DK2050818T3 (da) Transkriptionsaktivatorer med gradueret transaktiveringspotentiale
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
DE3772485D1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
ATE352638T1 (de) REVERSE ßTWO-HYBRIDß-SYSTEME
ATE214095T1 (de) Verwendung einer exo-nukleotidprobe in der genklonierung
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
HUP9802383A2 (hu) Transzkripciós szabályozó szekvenciák és eljárások alkalmazásukra
NO962188L (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
Polstein et al. Light-inducible gene regulation with engineered zinc finger proteins
DE59712319D1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
ATE366120T1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DK1097233T3 (da) Promotor for vækstdifferentieringsfaktor og anvendelser deraf
DE69715672D1 (de) Reporter-zellinie zum nachweis des cytomegalovirus und zur identifizierung von modulatoren der viralen genexpression
DE69233330D1 (de) Verwendung eines Inhibitors von Tau/Neurofilament-Proteinkinase PK40
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same
WO2001092578A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by retinoids
DE69821102D1 (de) Verwendung von calculus
WO2023230570A3 (en) Compositions and methods for modulating genetic drivers
WO1999005170A8 (en) NOVEL ESTROGEN β RECEPTOR AND ISOFORMS
ATE271608T1 (de) Inhibitorprotein der dna-gyrase.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition